Skip to content

Stipple Bio

1 viewer · 30d

Total raised

$65.1M

+$65.1M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $65.1M
ROUNDS
1
INVESTORS
15
FOUNDED
2021
HQ
Cambridge, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Stipple Bio is a Cambridge, Massachusetts precision oncology company founded in 2022 that develops cancer therapeutics targeting tumor-specific cell surface epitopes. Its Pointillist platform maps thousands of subtle molecular differences on cell surfaces to identify epitopes unique to tumors rather than relying on broadly expressed surface proteins. The lead candidate, STP-100, is an antibody drug conjugate built on tumor-specific binders and is expected to enter clinical studies in early 2027. The company emerged from stealth in April 2026 with a $100 million Series A co-led by RA Capital, a16z Bio+Health and Nextech Invest.

What sets it apart

Targets tumor-specific 'epitomics' — precise protein surface features unique to cancer cells — instead of tumor-specific gene expression, aiming to widen the therapeutic index by avoiding on-target/off-tumor toxicity. The platform is modality-agnostic, so discovered epitopes can be carried into formats beyond antibodies.

Funding history

1 round
EquityMar 31, 2026
Form D
+$65.1M$65.1M total

Latest SEC filings

via EDGAR · CIK 0001932776
Form D · Mar 31, 2026View on EDGAR

Products

1 tracked

Pointillist platform

Drug discovery platform

A discovery platform that systematically maps cell surface epitopes at high resolution to reveal differences unique to tumor cells, then generates binders against those tumor-specific epitopes for therapeutic development.

  • Epitope-resolution cellular profiling and target discovery
  • Maps thousands of molecular points to find tumor-specific surface differences
  • Modality-agnostic — not limited to antibody formats
  • Feeds a precision oncology pipeline led by STP-100

Links

WebsiteLinkedInSEC EDGAR filings